Abstract
Several medications are associated with retinal vascular toxicity. These include intraocular aminoglycosides, oral contraceptives, interferon alpha, several other agents, and talc, which occurs as a vehicle in some oral medications that may be abused intravenously. As a group, these entities represent a small but clinically relevant category of retinal toxicity from medications. Some of the manifestations (e.g., retinal vascular occlusion) are nonspecific, but others are more specific, including clinically visible talc emboli in retinal vessels. Toxicity may be asymptomatic or may cause irreversible visual loss. By maintaining a high index of suspicion, the correct diagnosis can usually be made.
Keywords: Retinal vascular toxicity, aminoglycosides, talc, oral contraceptives, interferon alpha.
Current Pharmaceutical Design
Title:Update on Pharmacologic Retinal Vascular Toxicity
Volume: 21 Issue: 32
Author(s): Stephen G. Schwartz, Andrzej Grzybowski, Weronika Wasinska-Borowiec, Harry W. Flynn and William F. Mieler
Affiliation:
Keywords: Retinal vascular toxicity, aminoglycosides, talc, oral contraceptives, interferon alpha.
Abstract: Several medications are associated with retinal vascular toxicity. These include intraocular aminoglycosides, oral contraceptives, interferon alpha, several other agents, and talc, which occurs as a vehicle in some oral medications that may be abused intravenously. As a group, these entities represent a small but clinically relevant category of retinal toxicity from medications. Some of the manifestations (e.g., retinal vascular occlusion) are nonspecific, but others are more specific, including clinically visible talc emboli in retinal vessels. Toxicity may be asymptomatic or may cause irreversible visual loss. By maintaining a high index of suspicion, the correct diagnosis can usually be made.
Export Options
About this article
Cite this article as:
Schwartz G. Stephen, Grzybowski Andrzej, Wasinska-Borowiec Weronika, Flynn W. Harry and Mieler F. William, Update on Pharmacologic Retinal Vascular Toxicity, Current Pharmaceutical Design 2015; 21 (32) . https://dx.doi.org/10.2174/1381612821666150909101621
DOI https://dx.doi.org/10.2174/1381612821666150909101621 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema
Current Drug Safety Involvement of Coagulation and Hemostasis in Inflammatory Bowel Diseases
Current Vascular Pharmacology Sirolimus Eluting Stent: A New Era in Interventional Cardiology?
Current Pharmaceutical Design Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism Vascular Endothelial Growth Factor (VEGF) Biochemistry and Development of Inhibitory Drugs
Current Drug Therapy Carbohydrates in Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation ANN Classification and Modified Otsu Labeling on Retinal Blood Vessels
Current Signal Transduction Therapy Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Stroke in Women
Recent Patents on Cardiovascular Drug Discovery Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Structure and Function of Myelinated Nerve Fibers in the Rabbit Eye Following Ischemia/Reperfusion Injury
Current Neurovascular Research Peptides Targeting Gap Junctional Structures
Current Pharmaceutical Design Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews